DRUG PATENTS AND EXCLUSIVITY: AN INVESTOR’S GUIDE
Education - New drugs are expensive and time-consuming to develop and market. Some studies estimate that the cost of bringing a drug to market—from R&D to FDA … Continue Reading
Read NowEducation
UNDERSTANDING THE FDA’S EXPEDITED APPROVAL PROCESSES
Education - How the FDA's approval processes differ, a investor's guide. Including Breakthrough Therapy, Accelerated Approval, Priority Review, and Fast Track.
Read Now
HIGH ANALYST PRICE TARGET: BEWARE THE CONFLICTS OF INTEREST
Education - The most quoted piece of information from analyst reports also happens to be the most useless. Price targets should be taken with a grain of … Continue Reading
Read Now
Video: Our April Strategy Webinar is Live
Education - A recording of last night’s webinar is now available! As usual, follow-up questions can be directed to editor@propthink.com. Register And Watch The Video Timestamps below. … Continue Reading
Premium: Read Now
Gauging Risk/Reward for the Sarepta Contrarian
Education - Across the world of biotech, few companies have seen the volatility of Sarepta Therapeutics (SRPT) in the last three years. With the stock in the … Continue Reading
Premium: Read Now
Year of the Bear? A Webinar
Education - Oil has yet to stabilize and investors are skittish about a rising interest rate environment; it's the first since 2004. China's economy is slowing, and their markets have tanked over the last few months. These are why equities can't find a bottom, according to the financial press, anyway.
Premium: Read Now
AN INVESTOR’S GUIDE TO THE “GOING PUBLIC” PROCESS
Education - One of the primary reasons that private companies go public is to lower the cost and increase the efficiency of raising additional capital. However, investors who are not … Continue Reading
Read Now